|
|
Post by morgieporgie on Jul 29, 2018 13:37:04 GMT -5
Maybe instead of sipping water before using the Afrezza you could advocate for Kool-Aid to be the refreshment of choice. What do you think? Not worthy of a response. Good grief. Maybe instead of thinking about how much money you're gonna make here, it's time to ask why the stock is currently priced at under 31 pennies a share - before counting the reverese split of course. Get grounded maybe. Clearly you fell in love here, it happens. |
|
|
|
Post by sweedee79 on Jul 29, 2018 13:53:37 GMT -5
morgieporgie. Has nothing to do with being "grounded" . Jeez "fell in love" LOL .. We have differences of opinions here. And I don't see the point of someone trying to get me or anyone else to "face reality" .. clearly I see reality ..
|
|
|
|
Post by nylefty on Jul 29, 2018 14:00:14 GMT -5
Not worthy of a response. Good grief. Maybe instead of thinking about how much money you're gonna make here, it's time to ask why the stock is currently priced at under 31 pennies a share - before counting the reverese split of course. Get grounded maybe. Clearly you fell in love here, it happens. What are you talking about? When did I say anything about how much money I'm going to make here? Others have posted daydreams about the fortunes they're going to make with this investment, but not me. |
|
|
|
Post by uvula on Jul 29, 2018 14:04:49 GMT -5
I'm frustrated with our situation (like all of us) and reading the message boards is making it worse. I'm going to try to avoid spending so much time here.
|
|
|
|
Post by sportsrancho on Jul 29, 2018 14:08:53 GMT -5
I'm frustrated with our situation (like all of us) and reading the message boards is making it worse. I'm going to try to avoid spending so much time here. Yes, I think that was nylefty point:-) |
|
|
|
Post by mnkdfann on Jul 29, 2018 14:13:38 GMT -5
I'm frustrated with our situation (like all of us) and reading the message boards is making it worse. I'm going to try to avoid spending so much time here. I recommend visiting Australia. During the 10 or so days I was there recently, I only viewed this site a handful of times and I think I only posted thrice.  |
|
|
|
Post by mnkdfann on Jul 29, 2018 14:19:27 GMT -5
Great! So maybe it's best you sit back and think how great the product is, if that works for you. Some people prefer to know why things are the way they are and how to fix or change it. Like a previous poster said, " facts aren't negative or positive" they are the truth. The stock is at multi-year lows, that's factual. To me, why is the question. "Facts don't do what I want them to Facts just twist the truth around" - Crosseyed and Painless, Talking Heads (Full Disclosure, I'm seeing David Byrne in concert next Friday!) www.lyricsfreak.com/t/talking+heads/crosseyed+painless_20135079.html |
|
|
|
Post by golfeveryday on Jul 29, 2018 14:31:36 GMT -5
Anyone happen to notice management always talks a big game, like they have some huge partner lined up? Then when the truth is revealed, it ends up being some no name player in the industry? Let's be real here, this is no deal with Takeda or Abbott or Dexcom.. These seem like last minute deals, or agreements of understanding - like with One Drop. Nothing seems to bear fruit. Sorry to be negative here but it's very frustrating! I think your problem is your expectations need to be reset.
As a product afrezza is exceeding what most, except maybe Al Mann expected. Do a google on afrezza lawsuits and then do a google on Trulicity. While MNKD was notified their REMs was no longer needed. Pfizer was allowed to update their label with additional warnings of death.
Four years after approval, Trulicity is doing $2B a year in sales and afrezza is a niche drug. Why? GLP-1 is in the standard of care and inhaled insulin for T2s is not. With all the other lawsuits against the other GLP-1s Trulicity is the safest of the dangerous.
The big game "talk" I have been hearing lately is from Dr. Kendall. He called afrezza a "superior" insulin a few weeks ago. To be honest that takes a huge "set" for a guy with his reputation and standing in the community if he is wrong. Dr. Kendall said “The research and clinical response to Afrezza as a mealtime insulin supports ongoing efforts to establish this product as the standard of care for those living with type 1 or type 2 diabetes”. Getting the "Standards" updated is a process and will be done in stages and will not happen overnight. The great news for PWDs, Mannkind, and Mannkind shareholders there is probably no one better able to pull off these updates. Once they occur afrezza will no longer be the niche drug it is today and will become mainstream. Exceeding Trulicity sales once the standard should be very doable.
Amazon was raised by Jeff Dachis at the 2017 shareholders meeting. Jeff is currently concluding his afrezza trial at One Drop. What we know about afrezza is when properly dosed afrezza always wins.
RLS is a mystery to me. However Paul Allen and others were made up by bloggers seeing a connection with MSFT. My understanding and maybe incorrectly was Kevin Johnson was the main guy. However can you imagine if RLS becomes real and afrezza becomes the standard? Just saying, one can dream.
if it gets included in SOC for T1 then market will assume T2 is possible and price it in. T1 will certainly push the price north and anticipation of T2, well, much more. Didn’t ADA say they would change their recommendations more often due to innovations? |
|
|
|
Post by morgieporgie on Jul 29, 2018 14:39:17 GMT -5
morgieporgie. Has nothing to do with being "grounded" . Jeez "fell in love" LOL .. We have differences of opinions here. And I don't see the point of someone trying to get me or anyone else to "face reality" .. clearly I see reality .. Nobody said anything about getting anyone to "face reality". The truth is the stock is at all time lows. The truth is those cash upfront deals aren't happening. The good thing to me is that management is getting things done and I love that they hired Kendall as CMO. Truth hurts sometimes, but I think it's healthy to know it. |
|
|
|
Post by mnholdem on Jul 29, 2018 16:00:27 GMT -5
morgieporgie you've made your point. Move on...this repetitiveness against other viewpoints is beginning to resemble harassment. Thank you! 
|
|
|
|
Post by morgieporgie on Jul 29, 2018 16:03:12 GMT -5
morgieporgie you've made your point. Move on...this repetitiveness against other viewpoints is beginning to resemble harassment. Thank you! Got it, thank you. |
|
|
|
Post by rockstarrick on Jul 29, 2018 16:06:03 GMT -5
What does that have to do with the current MannKind management? Answer: Nothing. You're using the same outdated bashes that the shorts use on StockTwits. Correct, it has nothing to do with current management. Those words are from Al Mann himself. I challenge you to find one comment, “embarrassment of riches”, “stay tuned”, “position of strength” , that was made by Al Mann. Al never said anything other than “take care of the Patients and the Shareprice will take care of itself” Al never mislead anybody !! He put his money where his mouth was, and fought for what is most likely, one of the most significant advancements in care, that those living with Diabetes will ever see. Its one thing to sit on a stock message board and vent about the shareprice of Mannkind, but to just barf out bullshit statements such as this, make you appear either either stupid, or dishonest. If you’re going to put false words in somebody’s mouth, at least make it someone who can defend against the BS. 🤬 |
|
|
|
Post by sayhey24 on Jul 29, 2018 16:31:55 GMT -5
I think your problem is your expectations need to be reset.
As a product afrezza is exceeding what most, except maybe Al Mann expected. Do a google on afrezza lawsuits and then do a google on Trulicity. While MNKD was notified their REMs was no longer needed. Pfizer was allowed to update their label with additional warnings of death.
Four years after approval, Trulicity is doing $2B a year in sales and afrezza is a niche drug. Why? GLP-1 is in the standard of care and inhaled insulin for T2s is not. With all the other lawsuits against the other GLP-1s Trulicity is the safest of the dangerous.
The big game "talk" I have been hearing lately is from Dr. Kendall. He called afrezza a "superior" insulin a few weeks ago. To be honest that takes a huge "set" for a guy with his reputation and standing in the community if he is wrong. Dr. Kendall said “The research and clinical response to Afrezza as a mealtime insulin supports ongoing efforts to establish this product as the standard of care for those living with type 1 or type 2 diabetes”. Getting the "Standards" updated is a process and will be done in stages and will not happen overnight. The great news for PWDs, Mannkind, and Mannkind shareholders there is probably no one better able to pull off these updates. Once they occur afrezza will no longer be the niche drug it is today and will become mainstream. Exceeding Trulicity sales once the standard should be very doable.
Amazon was raised by Jeff Dachis at the 2017 shareholders meeting. Jeff is currently concluding his afrezza trial at One Drop. What we know about afrezza is when properly dosed afrezza always wins.
RLS is a mystery to me. However Paul Allen and others were made up by bloggers seeing a connection with MSFT. My understanding and maybe incorrectly was Kevin Johnson was the main guy. However can you imagine if RLS becomes real and afrezza becomes the standard? Just saying, one can dream.
if it gets included in SOC for T1 then market will assume T2 is possible and price it in. T1 will certainly push the price north and anticipation of T2, well, much more. Didn’t ADA say they would change their recommendations more often due to innovations? I would agree. If the market sees Dr. Kendall deliver on the T1 inclusion there is little reason they should not think he will also be able to change the current T2 standard. However, the T2 hill is much steeper but the rewards significantly larger. Having t come before GLP-1 use would be huge and take the Trulicity market. Having it in its proper place which would be as step 1 with or without metformin and you are easily looking at 10x the IPO price. |
|
|
|
Post by morgieporgie on Jul 29, 2018 16:33:52 GMT -5
Correct, it has nothing to do with current management. Those words are from Al Mann himself. I challenge you to find one comment, “embarrassment of riches”, “stay tuned”, “position of strength” , that was made by Al Mann. Al never said anything other than “take care of the Patients and the Shareprice will take care of itself” Al never mislead anybody !! He put his money where his mouth was, and fought for what is most likely, one of the most significant advancements in care, that those living with Diabetes will ever see. Its one thing to sit on a stock message board and vent about the shareprice of Mannkind, but to just barf out bullshit statements such as this, make you appear either either stupid, or dishonest. If you’re going to put false words in somebody’s mouth, at least make it someone who can defend against the BS. 🤬 Maybe Al wasn't the one who said that. My mistake, hey listen I make mistakes. I thought he did. Anyways, look, I believe in Afrezza as much as anyone here. Not happy with the companies' performance. It's that simple. No need to play message board barbarian. Let's talk why management can't execute. |
|
|
|
Post by sportsrancho on Jul 29, 2018 16:35:46 GMT -5
It was Matt that said it and he’ll never live it down, but who knows maybe he’ll be living it up someday:-)) Hasn’t sold a share.
|
|
